7 active not recruiting. 7 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Active not recruiting 7 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Refractory Multiple Myeloma: new trials by email Literature Review of Refractory Multiple Myeloma trials Research Report on Refractory Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma RO7875913, Placebo, Cevostamab - Healthy Volunteers, Relapsed Multiple Myeloma | Phase 1 | Active not recruiting | Genentech, Inc. | 240 | 2026-03-11 | 2026-09-30 |
| Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Active not recruiting | Abdullah Khan | 12 | 2023-12-21 | 2026-05-13 |
| A Study of MCARH109 and MCARH125 in People With Multiple Myeloma MCARH125, MCARH109 - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 15 | 2022-06-20 | 2026-07-06 |
| Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma Manufactured Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide - Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 1 | Active not recruiting | Thomas Martin, MD | 5 | 2021-10-18 | 2026-02-20 |
| TriPRIL CAR T Cells in Multiple Myeloma TriPRIL CAR T Cells, Cyclophosphamide, Fludarabine - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Active not recruiting | Marcela V. Maus, M.D.,Ph.D. | 16 | 2021-10-05 | 2026-08-07 |
| Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial Carfilzomib, Dexamethasone, Pomalidomide - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 39 | 2021-05-06 | 2026-02-25 |
| CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma Carfilzomib, Dexamethasone, Telaglenastat Hydrochloride - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 19 | 2019-07-08 | 2026-07-20 |
Multiple Myeloma (7)
Blood Protein Disorders (7) · Cardiovascular Diseases (7) · Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Hemorrhagic Disorders (7) · Hemostatic Disorders (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms, Plasma Cell (7) · Paraproteinemias (7) · Vascular Diseases (7)
Calcium Dobesilate (3) · Dexamethasone (3) · auricularum (3) · dexamethasone 21-phosphate (3) · dexamethasone acetate (3) · Biopsy (2) · Cyclophosphamide (2) · Magnetic Resonance Spectroscopy (2) · Phantoms, Imaging (2) · Specimen Handling (2) · X-Rays (2) · carfilzomib (2) · fludarabine (2) · fludarabine phosphate (2) · elotuzumab (1)
Abdullah Khan (1) · Genentech, Inc. (1) · Marcela V. Maus, M.D.,Ph.D. (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Thomas Martin, MD (1)
United States (6) · New Zealand (1)
Abdullah M Khan, MBBS, MSc (1) · Anupama Kumar, MD (1) · Matthew J Frigault, MD (1) · Prashant Kapoor, M.D. (1) · Sham Mailankody, MBBS (1) · Wilson I Gonsalves (1)
UM1CA186686 (1)